Spots Global Cancer Trial Database for pi3k inhibitors
Every month we try and update this database with for pi3k inhibitors cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
A Dose Escalation Study of SF1126, a PI3 Kinase (PI3K) Inhibitor, Given By Intravenous (IV) Infusion in Patients With Solid Tumors | NCT00907205 | Advanced or Met... Cancer Solid Cancers | SF1126 | 18 Years - | Semafore Pharmaceuticals | |
A Study of GDC-0941 in Patients With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma for Which Standard Therapy Either Does Not Exist or Has Proven Ineffective or Intolerable | NCT00876122 | Non-Hodgkin's L... | GDC-0941 | 18 Years - | Genentech, Inc. | |
A Study of GDC-0941 in Patients With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma for Which Standard Therapy Either Does Not Exist or Has Proven Ineffective or Intolerable | NCT00876122 | Non-Hodgkin's L... | GDC-0941 | 18 Years - | Genentech, Inc. | |
A Study of GDC-0941 in Participants With Locally Advanced or Metastatic Solid Tumors for Which Standard Therapy Either Does Not Exist or Has Proven Ineffective or Intolerable | NCT00876109 | Solid Cancers | GDC-0941 | 18 Years - | Genentech, Inc. |